We’re only one week away from our annual Bay Area life sciences forum, State of the Biotech Union—and this is your last chance to save $120. This special event takes place on Tuesday, December 6th, at the Amgen campus in South San Francisco.
This year, we’re holding a series of post-election discussions to assess where biotech and healthcare is heading after the stunning election of Donald Trump.
Jacob Corn of Berkeley’s Innovative Genomics Initiative, Matthew Porteus of Stanford University, and Marcy Darnovsky of the Center for Genomics and Society will sit down for a frank discussion of gene editing: Its near-term promise to heal dire diseases, but also the caution that scientists and policy makers must employ as the field moves quickly forward.
John Wilbanks of Sage Bionetworks and Vijay Pande of Andreessen Horowitz are on board to talk about the convergence of biotech, health policy, and information technology, one from the nonprofit side, the other from the venture point of view.
Any national health conversation requires an assessment of our preparedness for emerging threats such as Zika virus. We’ll ask top virologist Melanie Ott, of the Gladstone Institutes, and Nima Farzan of biotech firm PaxVax if scientists and health officials are on the right track.
Finally, we’ll end the day with a talk from Peter Kuhn of the University of Southern California, whose work spans several disciplines but focuses on cancer. He’ll dive into the Obama administration’s “cancer moonshot” initiative—and why the ambitious national science project is necessary under Trump. After Peter, a panel spanning the drug industry, venture capital, nonprofit funding, and health economics will forecast the next four years of health and life science policy and which technical advances could be helped—or hindered—in the new political landscape.
Please join us on Dec. 6! Our speakers include: